BIMINI Biotech develops first-in-class therapeutics targeting the Wiskott-Aldrich-Syndrome protein (WASp) to treat hematological cancers. Their proprietary small molecule WASP modulators demonstrate potent anti-cancer effects, addressing the need for effective treatments in this challenging area of oncology.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TPFounders
Product
Problem
Many hematological cancers, such as lymphoma and leukemia, have high relapse rates and limited treatment options, especially for elderly patients with comorbidities. Current therapies often fail, and newer targeted agents with novel mechanisms of action are needed to improve treatment outcomes.
Solution
BIMINI Biotech is developing first-in-class small molecule therapeutics that target the Wiskott-Aldrich Syndrome protein (WASp), an actin nucleation-related protein expressed exclusively in hematopoietic cells. Their proprietary WASp modulators, including agonists and antagonists, have demonstrated potent anti-cancer effects by inducing genomic instability in lymphoma cells, leading to cancer cell death. BIMINI's lead candidate, BM-011, a WASp activator, has shown promising in vitro and in vivo anti-cancer effects across various lymphoma models, including those resistant to existing treatments. By modulating WASp, BIMINI aims to provide a novel therapeutic approach for hematological malignancies and autoimmune disorders.
Target Audience
The primary target audience includes patients with relapsed or refractory lymphomas and leukemias, as well as researchers and clinicians seeking novel therapeutic approaches for hematological malignancies and autoimmune disorders.
Features
- Proprietary portfolio of small molecule WASp modulators (agonists and antagonists)
- BM-011: A WASp agonist demonstrating potent activity in various lymphoma models
- Unique mechanism of action inducing genomic instability in lymphoma cells
- Potential application in autoimmune disorders through WASp modulation
- In vitro and in vivo validation of anti-cancer effects for different lymphoma models